259 related articles for article (PubMed ID: 12822071)
1. [Mutations in the dihydropyrimidine dehydrogenase gene and their role in 5-fluororuracil intolerance].
Gross E; Seck K; Kiechle M
Zentralbl Gynakol; 2002 Dec; 124(12):574-9. PubMed ID: 12822071
[TBL] [Abstract][Full Text] [Related]
2. A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency.
Ezzeldin H; Okamoto Y; Johnson MR; Diasio RB
Anal Biochem; 2002 Jul; 306(1):63-73. PubMed ID: 12069415
[TBL] [Abstract][Full Text] [Related]
3. Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects.
Gross E; Ullrich T; Seck K; Mueller V; de Wit M; von Schilling C; Meindl A; Schmitt M; Kiechle M
Hum Mutat; 2003 Dec; 22(6):498. PubMed ID: 14635116
[TBL] [Abstract][Full Text] [Related]
4. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients.
Ezzeldin HH; Lee AM; Mattison LK; Diasio RB
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8699-705. PubMed ID: 16361556
[TBL] [Abstract][Full Text] [Related]
5. Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity.
Ezzeldin H; Johnson MR; Okamoto Y; Diasio R
Clin Cancer Res; 2003 Aug; 9(8):3021-8. PubMed ID: 12912951
[TBL] [Abstract][Full Text] [Related]
6. Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity.
Kouwaki M; Hamajima N; Sumi S; Nonaka M; Sasaki M; Dobashi K; Kidouchi K; Togari H; Wada Y
Clin Cancer Res; 1998 Dec; 4(12):2999-3004. PubMed ID: 9865912
[TBL] [Abstract][Full Text] [Related]
7. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
van Kuilenburg AB
Eur J Cancer; 2004 May; 40(7):939-50. PubMed ID: 15093568
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.
Raida M; Schwabe W; Häusler P; Van Kuilenburg AB; Van Gennip AH; Behnke D; Höffken K
Clin Cancer Res; 2001 Sep; 7(9):2832-9. PubMed ID: 11555601
[TBL] [Abstract][Full Text] [Related]
9. Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy.
Amstutz U; Farese S; Aebi S; Largiadèr CR
J Exp Clin Cancer Res; 2008 Oct; 27(1):54. PubMed ID: 18937829
[TBL] [Abstract][Full Text] [Related]
10. [Dihydropyrimidine dehydrogenase activity and its genetic aberrations].
Ogura K
Gan To Kagaku Ryoho; 2006 Aug; 33(8):1041-8. PubMed ID: 16912518
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene.
van Kuilenburg AB; Haasjes J; Richel DJ; Zoetekouw L; Van Lenthe H; De Abreu RA; Maring JG; Vreken P; van Gennip AH
Clin Cancer Res; 2000 Dec; 6(12):4705-12. PubMed ID: 11156223
[TBL] [Abstract][Full Text] [Related]
12. Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population.
Hsiao HH; Yang MY; Chang JG; Liu YC; Liu TC; Chang CS; Chen TP; Lin SF
Cancer Chemother Pharmacol; 2004 May; 53(5):445-51. PubMed ID: 15132136
[TBL] [Abstract][Full Text] [Related]
13. [Pro or con the phenotyping/genotyping of patients treated by 5-Fluorouracil to prevent adverse drug reactions?].
Coriat R; Chaussade S
Therapie; 2007; 62(2):105-9. PubMed ID: 17582310
[TBL] [Abstract][Full Text] [Related]
14. Two cases of 5-fluorouracil toxicity linked with gene variants in the DPYD gene.
Ofverholm A; Arkblad E; Skrtic S; Albertsson P; Shubbar E; Enerbäck C
Clin Biochem; 2010 Feb; 43(3):331-4. PubMed ID: 19822137
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacogenetics in oncology: 5-fluorouracil and the dihydropyrimidine dehydrogenase].
Lazar A; Jetter A
Dtsch Med Wochenschr; 2008 Jul; 133(28-29):1501-4. PubMed ID: 18597209
[TBL] [Abstract][Full Text] [Related]
16. Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.
Lee A; Ezzeldin H; Fourie J; Diasio R
Clin Adv Hematol Oncol; 2004 Aug; 2(8):527-32. PubMed ID: 16163233
[TBL] [Abstract][Full Text] [Related]
17. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype.
Johnson MR; Wang K; Diasio RB
Clin Cancer Res; 2002 Mar; 8(3):768-74. PubMed ID: 11895907
[TBL] [Abstract][Full Text] [Related]
18. DPYD*2A mutation: the most common mutation associated with DPD deficiency.
Saif MW; Ezzeldin H; Vance K; Sellers S; Diasio RB
Cancer Chemother Pharmacol; 2007 Sep; 60(4):503-7. PubMed ID: 17165084
[TBL] [Abstract][Full Text] [Related]
19. Mutational spectrum of dihydropyrimidine dehydrogenase gene (DPYD) in the Tunisian population.
Ben Fredj R; Gross E; Chouchen L; B'Chir F; Ben Ahmed S; Neubauer S; Kiechle M; Saguem S
C R Biol; 2007 Oct; 330(10):764-9. PubMed ID: 17905396
[TBL] [Abstract][Full Text] [Related]
20. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.
Omura K
Int J Clin Oncol; 2003 Jun; 8(3):132-8. PubMed ID: 12851836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
